Department of Medicine.
Inova Schar Heart and Vascular, Inova Fairfax Hospital, Falls Church, Virginia.
Ann Am Thorac Soc. 2024 Dec;21(12):1706-1714. doi: 10.1513/AnnalsATS.202401-099OC.
The slope of decline in forced expiratory volume in 1 second (FEV) is commonly used to reflect the rate of disease progression for descriptive studies and therapeutic trials in chronic obstructive pulmonary disease (COPD). The frequency and duration of spirometric testing needed to report the true slope are unknown. We sought to define the minimum frequency and follow-up duration needed to accurately describe the annualized rate of FEV change among patients with moderate to very severe COPD. We performed a analysis of the annualized rate of FEV change among 4,412 subjects previously enrolled in the 4-year Understanding Potential Long-Term Impacts on Function with Tiotropium-or, UPLIFT-trial of tiotropium versus placebo. Slope estimates were modeled for different iterations of semiannual or annual testing over a variable duration up to 42 months. All models were compared with a reference of semiannual spirometry for 42 months. The overall annual rate of postbronchodilator FEV decline measured semiannually for 42 months (44.6 ml; 95% confidence interval [CI] = 42.5-46.6) did not differ significantly from annual spirometry over the same period (43.7 ml; 95% CI = 41.3-46.1) or semiannual spirometry over the first 2 years (44.3 ml; 95% CI = 41.1-47.5). Agreement was consistent for two follow-up values as far as 24 months apart (43.3 ml; 95% CI = 39.9-46.8). Models that are based on less than two follow-up values or a duration less than 18 months were characterized by relative underestimation of the slope. In a large cohort of patients with moderate to very severe COPD, the annualized rate of change in FEV was accurately represented by a minimum of two annual follow-up measurements over 18 months compared with semiannual testing over 42 months.
一秒用力呼气容积(FEV)的下降斜率通常用于反映慢性阻塞性肺疾病(COPD)描述性研究和治疗试验中的疾病进展速度。报告真实斜率所需的肺活量测定频率和随访时间尚不清楚。我们旨在确定准确描述中重度至极重度 COPD 患者 FEV 年变化率所需的最低频率和随访时间。我们对先前参加为期 4 年的噻托溴铵或噻托溴铵与安慰剂的理解潜在长期对功能影响(UPLIFT)试验的 4412 例患者的 FEV 年变化率进行了分析。对不同迭代的半年度或年度测试进行建模,测试持续时间可长达 42 个月。所有模型均与 42 个月半年度肺活量测定参考值进行比较。半年度测量支气管扩张剂后 FEV 下降的总体年率(44.6ml;95%置信区间[CI]为 42.5-46.6)与同期年度肺活量测定(43.7ml;95%CI为 41.3-46.1)或前 2 年的半年度肺活量测定(44.3ml;95%CI为 41.1-47.5)无显著差异。相隔 24 个月的两个随访值的一致性一致(43.3ml;95%CI为 39.9-46.8)。基于少于两个随访值或持续时间少于 18 个月的模型,其斜率相对低估。在一个大型中重度至极重度 COPD 患者队列中,与 42 个月半年度测试相比,至少进行两次年度随访测量可准确代表 FEV 年变化率,随访时间为 18 个月。